Skip to Content

New Drug Approvals Archive - May 2007

See also: New Indications and Dosage Forms for May 2007

May 2007

Perlane (dermal filler)

Date of Approval: May 2, 2007
Company: Medicis
Treatment for: Facial Wrinkles

Perlane is a dermal filler for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds.

Supprelin-LA (histrelin acetate) Subcutaneous Implant

Date of Approval: May 3, 2007
Company: Indevus Pharmaceuticals, Inc.
Treatment for: Precocious Puberty

Supprelin-LA is a once-yearly implant of the gonadotropin releasing hormone (GnRH) analog histrelin, indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children.

Neupro (rotigotine) Transdermal System

Date of Approval: May 9, 2007
Company: Schwarz Pharma
Treatment for: Parkinson's Disease, Restless Legs Syndrome

Neupro (rotigotine) is a dopamine agonist transdermal system indicated for the treatment of Parkinson’s disease and Restless Legs Syndrome.

Perforomist (formoterol fumarate) Inhalation Solution

Date of Approval: May 11, 2007
Company: Dey, L.P.
Treatment for: Chronic Obstructive Pulmonary Disease

Perforomist is an inhalation solution formulation of the long-acting beta(2)-adrenergic agonist formoterol fumarate, indicated for the long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

Seroquel XR (quetiapine) Tablets

Date of Approval: May 17, 2007
Company: AstraZeneca
Treatment for: Schizophrenia, Bipolar Disorder, Depression

Seroquel XR (quetiapine) is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia, bipolar disorder and as an adjunctive treatment to antidepressants in adults with Major Depressive Disorder.

Lybrel (levonorgestrel and ethinyl estradiol) Tablets

Date of Approval: May 22, 2007
Company: Wyeth Pharmaceuticals Inc.
Treatment for: Contraception

Marketing Status: Discontinued

Lybrel (levonorgestrel and ethinyl estradiol) is a low-dose combination contraceptive pill taken continuously (without a pill-free interval) and over time may eliminate scheduled menstrual periods. Lybrel is indicated for the prevention of pregnancy.

Xyzal (levocetirizine dihydrochloride)

Date of Approval: May 25, 2007
Company: UCB, Inc. and sanofi-aventis
Treatment for: Allergic Rhinitis, Allergic Urticaria

Xyzal (levocetirizine) is an antihistamine for the relief of symptoms associated with allergic rhinitis and urticaria.

Torisel (temsirolimus) Injection

Date of Approval: May 30, 2007
Company: Wyeth Pharmaceuticals, Inc.
Treatment for: Renal Cell Carcinoma

Torisel (temsirolimus), an inhibitor of mTOR kinase, is an antineoplastic agent indicated for the treatment of patients with advanced renal cell carcinoma.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.